The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats
- 260 Downloads
Cannabinoid type 1 (CB1) receptor antagonists are reportedly effective in reducing food intake both preclinically and clinically. This may be due in part to their effects on monoamine release in the brain. The level of central CB1 receptor occupancy underlying these neurobiological effects is unclear.
We explored the relationship between in vivo CB1 receptor occupancy in the frontal cortex and changes in both monoamine release in the medial prefrontal cortex (mPFC) and feeding behavior in rats in response to two orally administered CB1 receptor antagonists presently in clinical trials, SR141716A (rimonabant) and SLV319.
CB1 receptor occupancy was measured using [3H] SR141716A, and these occupancies were related to potencies to mediate increases in dopamine (DA) and norepinephrine (NE) release measured with microdialysis and decreases in consumption of a highly palatable diet (HP).
High receptor occupancy levels (>65%) were required to detect increases in monoamine release that were achieved with 3 and 10 mg/kg of SR141716A and 10 mg/kg of SLV319 for DA and 10 mg/kg of SR141716A for NE. Decreases in HP consumption were seen at occupancies higher than 65% for SR141716A that were achieved with 3 and 10 mg/kg. In contrast, decreases in HP consumption were seen at relatively low CB1 receptor occupancies (11%) for SLV319.
The occupancy method described here is an effective tool for interrelating central CB1 receptor occupancy with neurobiological actions of CB1 receptor antagonists and for furthering our understanding of the role of CB1 receptors in central nervous system physiology and pathology.
KeywordsSR141716A SLV319 [3H]SR141716A Dopamine Norepinephrine Microdialysis Receptor occupancy Feeding Cannabinoid In vivo binding
- Gallant A (1987) Nonlinear statistical models. Wiley, New YorkGoogle Scholar
- Lange J, Coolen H, van Stuivenberg H, Dijksman J, Herremans A, Ronken E, Keizer H, Hiskias G, Tipker K, McCreary A, Veerman W, Wals H, Stork B, Verveer P, den Hartog A, de Jong N, Adolfs T, Hoogendoorn J, Kruse C (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem 47:627–643PubMedCrossRefGoogle Scholar
- Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San DiegoGoogle Scholar
- Tzavara E, Davis R, Perry K, Li X, Salhoff C, Bymaster F, Witkin J, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544–553PubMedCrossRefGoogle Scholar